Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Peptide-based trial data, complex milestone payments, and frequent equity raises make Altimmune Inc’s disclosures tough to navigate. If you have ever searched “Altimmune SEC filings explained simply,” you already know the challenge: hundreds of pages packed with technical language and biotech accounting rules.
Stock Titan solves this problem with AI-powered summaries that turn every Altimmune quarterly earnings report 10-Q filing and Altimmune annual report 10-K simplified into plain-English insights. Our platform streams Altimmune Form 4 insider transactions real-time, flags cash-burn trends, and links each note in seconds—no more digging for footnotes on clinical trial spend. Need to monitor an unexpected disclosure? Our engine pushes alerts the moment an Altimmune 8-K material events explained notice hits EDGAR.
Whether you are comparing R&D expense trajectories or tracking Altimmune executive stock transactions Form 4, you will find every document in one place. Investors often ask, “Where can I review Altimmune proxy statement executive compensation details?” or “How should I interpret an Altimmune insider trading Form 4 transactions spike before data readouts?” Our expert commentary answers these questions and more, providing Altimmune earnings report filing analysis that ties revenue forecasts to trial timelines. By understanding Altimmune SEC documents with AI, you can evaluate dilution risk, anticipate capital needs, and follow pemvidutide’s clinical progress—all without wading through dense biotech jargon.
Altimmune, Inc. insider Christophe Arbet-Engels, the company's Chief Medical Officer, reported awards on 10/01/2025 consisting of 450,000 stock options with a $3.87 exercise price and 150,000 restricted stock units (RSUs). The options vest over four years with 25% vesting on 10/01/2026 and the remainder monthly over the next 36 months, subject to continued service. The RSUs vest over four years with 25% on 10/01/2026 and the remainder in annual installments over three years and have no expiration date. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Altimmune, Inc. (ALT) filed a Form 3 reporting that Christophe Arbet-Engels, serving as Chief Medical Officer and an officer/director, has no securities beneficially owned in the company as of the event date 10/01/2025. The filing notes a Power of Attorney (Exhibit 24) and is signed by Gregory Weaver, as Attorney-in-Fact on 10/03/2025. This is an initial ownership statement required by Section 16; it discloses the reporting person’s relationship to the issuer and that no equity or derivative holdings are reported on the form.
Catherine A. Sohn, a director of Altimmune, Inc. (ALT), was granted stock options covering 48,800 shares with an exercise price of $3.92. The options become vested and exercisable in substantially equal monthly installments over the 12 months following the 09/25/2025 grant date, and they expire on 09/25/2035. After the grant the reporting person beneficially owns 48,800 option shares on a direct basis. The grant is an equity-based director compensation intended to align interests with shareholders; if exercised it will convert into common stock.
Altimmune, Inc. (ALT) director Jerome Benedict Durso was granted stock options on 09/25/2025 to purchase 48,800 shares of common stock at an exercise price of $3.92 per share. The options become exercisable in substantially equal monthly installments over the 12 months following the grant date, subject to continued service. Following the grant, Durso beneficially owns 48,800 options. The Form 4 was filed by a single reporting person and signed by an attorney-in-fact on 09/29/2025.
Altimmune, Inc. (ALT) director Teri L. Lawver received a stock option grant on 09/25/2025 to purchase 48,800 shares of common stock at an exercise price of $3.92 per share. The option becomes exercisable in substantially equal monthly installments over the 12 months following 09/25/2025, subject to continued service, and expires on 09/25/2035. Following the reported transaction, the reporting person beneficially owns 48,800 option shares. The Form 4 was signed by an attorney-in-fact on 09/29/2025.
Diane Jorkasky, a director of Altimmune, Inc. (ALT), received a grant of stock options on 09/25/2025. The Form 4 shows an award of 48,800 stock options with an exercise price of $3.92 per share and an expiration date of 09/25/2035. The options were reported as acquired and are held directly by the reporting person. The shares underlying the option vest in substantially equal monthly installments over the 12 months following the grant date, subject to continued service. The filing was signed by Gregory Weaver as Attorney-in-Fact on 09/29/2025.
Altimmune insider activity: Director John Gill reports three items: a previously made bona fide gift of 2,714 shares of common stock, a correction that he currently holds zero shares directly or indirectly, and an option award for 48,800 shares with an exercise price of $3.92. The option was granted on the reported transaction date and vests monthly over 12 months beginning after the grant, with an exercise term extending roughly ten years from the grant date. The filing clarifies prior reporting errors that overstated his direct holdings by 57 shares and documents that the shares underlying the option are exercisable upon vesting.
Altimmune, Inc. (ALT) director Klaus Schafer reported receipt of a stock option award on 09/25/2025 that grants the right to buy 48,800 shares of common stock at an exercise price of $3.92 per share. The option becomes exercisable in substantially equal monthly installments over the 12 months following the grant date, subject to continued service, and expires on 09/25/2035. Following the reported transaction, the reporting person beneficially owns 48,800 option shares directly. The filing was submitted via counsel and signed by an attorney-in-fact on 09/29/2025.
Altimmune director Mitchel Sayare was granted an option to purchase 48,800 shares of common stock at a $3.92 exercise price. The option was granted on 09/25/2025, becomes exercisable in substantially equal monthly installments over the 12 months following that date, and expires on 09/25/2035. The reporting on Form 4 indicates the position is held directly. The filing is signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Altimmune (ALT)?
What is the market cap of Altimmune (ALT)?
